Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943dex312.htm |
| EX-31.1 - EX-31.1 - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943dex311.htm |
| EX-23.2 - EX-23.2 - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943dex232.htm |
| EX-23.1 - EX-23.1 - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943dex231.htm |
| EX-21 - EX-21 - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943dex21.htm |
| EX-10.18 - EX-10.18 - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943dex1018.htm |
| EX-3.1 - EX-3.1 - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943dex31.htm |
| 10-K - FORM 10-K - PROVECTUS BIOPHARMACEUTICALS, INC. | d289943d10k.htm |
Exhibit 32
CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND
CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14(b) UNDER
THE SECURITIES EXCHANGE ACT OF 1934 AND SECTION 1350 OF
CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE
Each of the undersigned, Timothy C. Scott, Ph.D. and John R. Glass, certifies, pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code, that (1) this Annual Report on Form 10-K for the year ended December 31, 2016 of Provectus Biopharmaceuticals, Inc. (the “Company”) fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act, and (2) the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| This Certification is signed on March 31, 2017. | /s/ Timothy C. Scott, Ph.D. | |||||
| Timothy C. Scott, Ph.D. | ||||||
| President (principal executive officer) | ||||||
| /s/ John R. Glass | ||||||
| John R. Glass | ||||||
| Interim Chief Financial Officer (principal financial officer) | ||||||